Wegovy side effects are most commonly gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain occur in 20% to 44% of users during clinical trials, usually peaking during dose escalation and easing with time. Serious but rare risks on the FDA label include pancreatitis, gallbladder disease, and kidney injury from dehydration. Understanding what to expect and how to manage symptoms makes this once-weekly injection considerably easier to tolerate.
What Wegovy Is and How It Works
Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly injectable approved by the FDA in June 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus a weight-related condition. In 2022 it was approved for adolescents aged 12 and older, and in 2024 the label was expanded to include reducing the risk of major cardiovascular events in adults with cardiovascular disease.
Semaglutide is a GLP-1 receptor agonist. It mimics the natural gut hormone GLP-1, which slows gastric emptying, enhances insulin response to meals, suppresses glucagon, and reduces appetite signaling in the hypothalamus. The same molecule is marketed as Ozempic at lower doses for type 2 diabetes and as oral Rybelsus tablets.
Common Wegovy Side Effects
The table below summarizes the most frequent adverse events from the 68-week STEP 1 phase 3 trial, which enrolled 1,961 adults.
| Side Effect | Wegovy 2.4 mg | Placebo | Usual Pattern |
|---|---|---|---|
| Nausea | 44% | 16% | Worst during titration |
| Diarrhea | 32% | 12% | Early weeks |
| Vomiting | 25% | 6% | After dose increases |
| Constipation | 24% | 11% | Ongoing; dietary |
| Abdominal pain | 20% | 10% | Variable |
| Headache | 14% | 10% | Variable |
| Fatigue | 11% | 5% | First weeks |
| Dyspepsia / heartburn | 9% | 3% | Ongoing |
In STEP 1, about 7% of Wegovy users stopped the drug due to GI side effects, compared with 3% on placebo. Most participants who stayed on treatment found symptoms improved after the 16-week titration period.
Serious Warnings on the FDA Label
- Boxed warning — thyroid C-cell tumors: Based on rodent studies; human relevance is unclear. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Pancreatitis: Stop Wegovy and seek care for severe, persistent abdominal pain, especially radiating to the back.
- Gallbladder disease: Rapid weight loss raises risk of gallstones and cholecystitis.
- Acute kidney injury: Often linked to vomiting or diarrhea causing dehydration.
- Hypoglycemia: Mostly a concern when combined with insulin or sulfonylureas; dose adjustments are often needed.
- Diabetic retinopathy complications: Rapid glucose improvement can transiently worsen pre-existing retinopathy.
- Increased heart rate: Small average rise of 1-4 bpm.
- Suicidal ideation and depression: Monitor for mood changes.
- Serious allergic reactions: Rare anaphylaxis and angioedema have been reported.
Why Titration Matters
Wegovy is started at 0.25 mg weekly for the first four weeks, then doubled every four weeks (0.5 mg, 1.0 mg, 1.7 mg) until reaching the 2.4 mg maintenance dose at week 17. Skipping ahead or escalating faster sharply increases nausea and vomiting. If side effects are severe at any step, your prescriber can hold the dose or step back temporarily.
Managing Common Side Effects
- Eat smaller, lower-fat, lower-sugar meals and stop when comfortably full
- Stay hydrated — aim for steady water intake, especially if nausea or diarrhea is present
- Add fiber gradually or consider a stool softener for constipation
- Avoid lying down immediately after eating to reduce reflux
- Time the injection for an evening or weekend when side effects are less disruptive
- Choose a consistent injection day and set a weekly reminder to avoid missed or doubled doses
- Rotate injection sites among the abdomen, thigh, and upper arm to prevent skin reactions
If a side effect is severe or persistent — vomiting that prevents hydration, abdominal pain radiating to the back, signs of dehydration, or rapid heart-rate changes — stop the next dose and contact your clinician before proceeding. Most people who continue past the titration phase report that GI symptoms fade significantly by the maintenance dose at week 17.
Where Wegovy Fits in a Treatment Plan
Wegovy is most effective when paired with diet and physical activity. It is FDA-approved for weight management, not for prediabetes specifically, but many people with prediabetes who also meet weight criteria are prescribed it. Lifestyle-based approaches — including a prediabetes-friendly diet and regular movement — remain first-line, and prediabetes is often reversible without medication.
The Bottom Line
Wegovy side effects are overwhelmingly gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain that are typically mild to moderate and improve after the 16-week titration. Rare but serious risks include pancreatitis, gallbladder disease, and kidney injury. Proper screening, slow titration, hydration, and dietary adjustments make most courses tolerable. Always consult a qualified clinician before starting or changing Wegovy.
This article is educational and does not replace personalized medical advice.
